Allogene Therapeutics, Inc. (ALLO)
Largest Insider Buys in Sector
ALLO Stock Price History Chart
ALLO Stock Performance
About Allogene Therapeutics, Inc.
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL. The company also develops ALLO-501, an anti-CD19 allogeneic CAR T cell product candidate that is in Phase I clinical trial for the treatment of R/R non-Hodgkin …
Insider Activity of Allogene Therapeutics, Inc.
Over the last 12 months, insiders at Allogene Therapeutics, Inc. have bought $5M and sold $108,503 worth of Allogene Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Allogene Therapeutics, Inc. have bought $6.97M and sold $28.82M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Belldegrun Arie (director) — $5M. Parker Geoffrey M. (CHIEF FINANCIAL OFFICER) — $2,049.
The last purchase of 1,724,137 shares for transaction amount of $5M was made by Belldegrun Arie (director) on 2024‑05‑16.
List of Insider Buy and Sell Transactions, Allogene Therapeutics, Inc.
| 2024-12-09 | Sale | director | 9,136 0.0042% | $2.18 | $19,916 | -9.25% | ||
| 2024-12-05 | Sale | director | 9,221 0.0044% | $2.16 | $19,917 | -3.27% | ||
| 2024-06-18 | Sale | director | 18,641 0.008% | $2.28 | $42,488 | +17.94% | ||
| 2024-05-30 | Sale | director | 11,200 0.0051% | $2.34 | $26,181 | +4.88% | ||
| 2024-05-16 | director | 1.72M 0.9747% | $2.90 | $5M | -14.00% | |||
| 2024-01-30 | CHIEF FINANCIAL OFFICER | 190 0.0001% | $3.60 | $683 | -22.76% | |||
| 2023-12-18 | Sale | director | 18,640 0.0103% | $2.70 | $50,317 | -0.86% | ||
| 2023-08-07 | Sale | director | 10,000 0.0069% | $4.29 | $42,855 | -25.59% | ||
| 2023-02-13 | Sale | General Counsel | 3,000 0.002% | $6.85 | $20,550 | -40.59% | ||
| 2023-01-17 | Sale | General Counsel | 3,000 0.0021% | $7.04 | $21,120 | -31.37% | ||
| 2022-12-15 | Sale | General Counsel | 5,602 0.0041% | $7.53 | $42,186 | -29.66% | ||
| 2022-08-11 | Sale | 15,000 0.0106% | $16.75 | $251,250 | -61.71% | |||
| 2022-08-02 | Sale | EVP of R&D and CMO | 2,000 0.0013% | $11.97 | $23,940 | -47.84% | ||
| 2022-07-05 | Sale | EVP of R&D and CMO | 2,000 0.0014% | $11.44 | $22,880 | -38.52% | ||
| 2022-06-22 | Sale | 10,000 0.0069% | $11.76 | $117,600 | -33.78% | |||
| 2022-06-21 | Sale | EVP of R&D and CMO | 2,000 0.0014% | $11.18 | $22,360 | -30.17% | ||
| 2022-05-19 | Sale | EVP of R&D and CMO | 11,500 0.0079% | $7.40 | $85,092 | +18.54% | ||
| 2022-03-15 | Sale | President and CEO | 23,648 0.0164% | $7.65 | $180,879 | +21.54% | ||
| 2022-03-15 | Sale | General Counsel | 8,849 0.0062% | $7.68 | $67,962 | +21.54% | ||
| 2022-03-15 | Sale | EVP of R&D and CMO | 5,169 0.0036% | $7.71 | $39,848 | +21.54% |
Insider Historical Profitability
| Belldegrun Arie | director | 1724137 0.8223% | $1.87 | 4 | 0 | <0.0001% |
| Parker Geoffrey M. | CHIEF FINANCIAL OFFICER | 819590 0.3909% | $1.87 | 1 | 0 | |
| Humer Franz B | director | 307507 0.1467% | $1.87 | 1 | 2 | +2.3% |
| PFIZER INC | 10 percent owner | 22032040 10.5079% | $1.87 | 1 | 0 | +2.3% |
| TPG Group Holdings (SBS) Advisors, Inc. | 10 percent owner | 18716306 8.9265% | $1.87 | 1 | 17 | +2.3% |
Institutional Investor Ownership
| Fidelity Investments | $113.38M | 12.17 | 25.36M | +0.48% | +$546,676.53 | 0.01 | |
| Tpg Gp A Llc | $83.66M | 8.98 | 18.72M | 0% | +$0 | 1.62 | |
| BlackRock | $43.15M | 4.63 | 9.65M | -3.49% | -$1.56M | <0.01 | |
| State Street | $41.05M | 4.41 | 9.18M | +278.37% | +$30.2M | <0.01 | |
| The Vanguard Group | $36.69M | 3.94 | 8.21M | -9.12% | -$3.68M | <0.01 |